Skip to content
  • Friday, 14 August 2026
  • 11:24 pm
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jul 5, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 27, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 20, 2026 0

Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…

Read More
Laboratory Automation & Robotics

J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push

Lana Keisha Jun 13, 2026 0

More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…

Read More
UT Dallas Researchers Reveal Aging Does Not Dictate Cognitive Decline as Brain Health Improves Across the LifespanBlood Vitamin C Levels Linked to Brain Volume and Connectivity in Large Study of Older AdultsAI Lab Result Interpretation Gains Traction with Patients, but Raises Accuracy and Validation Concerns for Clinical LaboratoriesJohnson & Johnson’s Icotyde Poised to Challenge AbbVie’s Skyrizi in Plaque Psoriasis Market
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ